"I only use kratom" — why that still qualifies for MAT
A lot of people who would benefit from treatment for kratom dependence never reach out, not because help is unavailable, but because they have convinced themselves they do not qualify. The internal reasoning usually sounds like this: it's kratom, not heroin. It's legal. It's a supplement. Real treatment is for people with real drug problems, and this probably doesn't count.
That belief is wrong pharmacologically, clinically, and as a way of deciding whether to ask for help. This page exists to address it directly.
Kratom dependence is opioid-type dependence. People whose only substance is kratom are treated with buprenorphine and report meaningful recovery. You do not need to have used anything other than kratom, injected anything, or reached any particular level of severity to be worth helping. If you are dependent and want to stop, that is the basis for getting care.
At a glance: the belief vs. the reality
Key Takeaways
- "Only kratom" is still opioid-type dependence. Kratom alkaloids act on the same mu-opioid receptors as heroin, oxycodone, and morphine. The biology is the same regardless of which substance a person used.
- Kratom use disorder is recognized and documented in the clinical literature. People whose primary or only substance is kratom are treated with buprenorphine and have published case reports describing successful outcomes.
- There is no minimum severity required. Eligibility is based on a pattern of dependence, difficulty stopping, and wanting help. A prescriber assesses this the same way they would assess any opioid use disorder.
- Getting help earlier leads to better outcomes. Waiting to be "bad enough" is backwards. The research on OUD consistently shows that earlier treatment is associated with better long-term results.
- The evaluation is a clinical conversation, not an audition. You do not need to prove severity or perform crisis. Honesty about what your use actually looks like is what helps the provider make an accurate assessment.
Where the "it's only kratom" belief comes from
The belief that kratom dependence does not count as a real substance use problem comes directly from how kratom is marketed and sold. It is positioned as a plant-based wellness product, shelved next to vitamins, and described with language borrowed from dietary supplements. When you buy something at a gas station under a label that says "natural energy blend," it does not feel like a drug problem is being created.
That framing is marketing. It has nothing to do with the pharmacology.
Kratom's alkaloids bind opioid receptors. Repeated activation of those receptors produces neuroadaptation, which is the same biological process that creates opioid dependence from any source. The brain does not distinguish between kratom mitragynine and oxycodone when it downregulates receptor sensitivity in response to chronic stimulation. The adaptation is the same. The withdrawal is the same pattern. The craving cycle is the same mechanism.
The "natural and legal" framing delays treatment for many people who end up coming in later, with deeper dependence, than they would have if they had reached out when the pattern first became clear. That delay does not help anyone.
Kratom dependence is opioid-type dependence
The clinical literature is consistent on this point. A 2026 AIM Clinical Cases paper in Annals of Internal Medicine by Barrett et al. described kratom and 7-OH dependence as resembling opioid use disorder clinically, recommended buprenorphine as the preferred treatment, and noted that best practice is to apply treatment of a similar duration to what is used for OUD.
A 2022 case series published in Substance Abuse (Broyan et al.) documented long-term buprenorphine treatment for kratom use disorder across multiple patients, with outcomes consistent with OUD treatment. The patients were not using other opioids. Kratom was their substance, and buprenorphine worked.
A 2023 case report in Cureus (Arhin et al.) documented successful management of kratom use disorder with buprenorphine and naloxone, noting that buprenorphine's mechanism of action at mu-opioid receptors made it the appropriate pharmacological match for kratom dependence.
The mechanism is why it works: buprenorphine is a high-affinity partial agonist at mu-opioid receptors, which is exactly where kratom's alkaloids act. It stabilizes the receptor system that kratom was activating, which is why it stops withdrawal and reduces cravings.
You don't have to be "bad enough"
This is the specific belief worth examining directly, because it is the one most likely to keep someone from reaching out.
MAT is not reserved for people at the most severe end of the spectrum. It is not only for people who have injected drugs, lost everything, or experienced overdose. The clinical basis for buprenorphine treatment is the presence of opioid use disorder, a pattern of compulsive use, difficulty stopping, and continued use despite harm, not which substance or how far things have gone.
People who use kratom and wonder whether they qualify often describe the same pattern:
- Noticing the dose has increased over months without intending it to
- Feeling sick, anxious, or unable to function without the product
- Trying to take days off and finding it harder than expected
- Spending more money on it than they meant to
- Thinking about it more than they would like to
If any of those sound familiar, the question is not whether you have hit a specific threshold. The question is whether the pattern has become something you want support to change.
A prescriber does not grade severity on a scale and give treatment only to people above a certain score. They evaluate whether dependence has developed, whether medication is likely to help, and what the appropriate plan is. Earlier treatment is consistently associated with better outcomes than later treatment. If anything, reaching out before things are at their worst puts you in a better position than waiting.
The question "am I bad enough?" is itself usually a sign that it is worth at least having an evaluation.
What qualifying actually looks like
Getting evaluated for kratom use disorder treatment is a clinical conversation, not a test you have to fail badly enough to pass. A licensed prescriber reviews:
- What you have been using (kratom, 7-OH, what products, how much)
- How long and how frequently
- What happens when you try to stop or reduce
- Your general health history and current medications
- Your goals
Based on that, they determine whether buprenorphine treatment is appropriate for your situation. They are not looking for the "worst" story. They are looking for an accurate picture.
You do not need to exaggerate your use to seem severe enough. You also do not need to minimize it to seem like you have things under control. Accurate information is what leads to the right clinical decision.
The evaluation can happen via telehealth in most states, often the same day you reach out. See how the process works at Bicycle Health. For the full overview of telehealth eligibility and rules, see Can You Get Suboxone for Kratom Addiction Online?
Frequently Asked Questions
Can you get Suboxone if you only use kratom?
Yes. Published case series and clinical guidance document buprenorphine treatment for people whose primary or only substance is kratom. Kratom use disorder is recognized clinically and treated with the same medication used for opioid use disorder because the pharmacological mechanism is the same. Whether it is appropriate for your specific situation is determined by a prescriber during an evaluation.
Do you need to have used heroin or other opioids to qualify for MAT?
No. MAT for opioid-type dependence is not limited to people who have used illicit opioids or who have severe dependence. The basis for treatment is the presence of opioid use disorder, which includes kratom and 7-OH dependence. Many people treated with buprenorphine for kratom dependence have no history of heroin, fentanyl, or other opioid use.
Is kratom dependence treated the same way as opioid dependence?
Clinically, yes. A 2026 AIM Clinical Cases paper described kratom and 7-OH dependence as pharmacologically similar to opioid use disorder and recommended applying buprenorphine treatment of a similar duration and approach. The medication works by the same mechanism regardless of which opioid-acting substance drove the dependence.
What if I am not sure I am dependent?
That uncertainty is worth exploring with a clinician rather than resolving on your own. Signs of dependence include needing more of the product over time to feel the same effect, feeling unwell or anxious when doses are skipped, and finding it harder to stop than expected. If any of those are present, a clinical evaluation is a low-commitment, no-pressure way to get an accurate picture of what is happening and whether support would help.
Does it matter how long I have been using kratom?
Duration of use affects the degree of dependence and the likely intensity of withdrawal, but it does not determine whether you qualify for treatment. People are treated for kratom use disorder after months of use and after years of use. Earlier treatment generally leads to better outcomes. There is no minimum time you need to have been using before reaching out.
Sources
- Barrett E, Hendy L, Lira MC, et al. What Clinicians Should Know About Kratom and 7-OH Mitragynine. AIM Clinical Cases (Annals of Internal Medicine: Clinical Cases). 2026;5:e251249. doi:10.7326/aimcc.2025.1249. https://www.acpjournals.org/doi/10.7326/aimcc.2025.1249
- Broyan VR, Brar JK, Allgaier Student T, et al. Long-term buprenorphine treatment for kratom use disorder: a case series. Substance Abuse. 2022;43:763-766. doi:10.1080/08897077.2021.2010250. PMID: 35112990.
- Arhin M, Mobley J, Hamad H, Remick P. Successful management of kratom use disorder with buprenorphine and naloxone. Cureus. 2023;15(6):e41146. doi:10.7759/cureus.41146. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386870/
- Wightman RS, et al. A Case of 7-OH Mitragynine Use Requiring Inpatient Medically Managed Withdrawal. Journal of Addiction Medicine. Published online August 4, 2025. doi:10.1097/ADM.0000000000001558. https://pubmed.ncbi.nlm.nih.gov/40758956/
- U.S. Food and Drug Administration. FDA and Kratom. FDA; updated February 2026. https://www.fda.gov/news-events/public-health-focus/fda-and-kratom
- Ruiz-Contreras HA, et al. Decoding kratom: molecular mechanisms and epigenetic factors in use and dependence. Translational Psychiatry. 2026. doi:10.1038/s41398-026-04022-5. https://www.nature.com/articles/s41398-026-04022-5
- Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorder. Publication No. PEP21-02-01-002. SAMHSA; 2021. https://library.samhsa.gov/product/tip-63-medications-opioid-use-disorder-executive-summary/pep21-02-01-003
- American Society of Addiction Medicine. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. ASAM; 2020.
- National Institute on Drug Abuse. Medications for Opioid Use Disorder. NIDA. Updated May 2025. https://nida.nih.gov/research-topics/medications-opioid-use-disorder
- Hammerslag LR, Mack A, Chandler RK, et al. Telemedicine buprenorphine initiation and retention in opioid use disorder treatment for Medicaid enrollees. JAMA Network Open. 2023;6(10):e2336914. doi:10.1001/jamanetworkopen.2023.36914.